Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up

Fawaz Al-Qahtani¹*, Nasser Alqhtani², Darshan Devang Divakar³, Fahad Alkhtani⁴ and Firas K. Alqarawi⁵

Abstract

Background: There are no studies that have assessed advanced glycation end products (AGEs) and interleukin 17A (IL-17A) levels in whole saliva (WS) of patients with dental implants. The aim was to compare levels of AGEs and IL-17A in WS and peri-implant clinical and radiographic status of patients with and without osteoporosis at 6-years’ follow-up.

Methods: Osteoporotic (Group-1) and systemically healthy controls (Group-2) having undergone dental implant therapy at least 5 years ago were included. A questionnaire was used to collect information about age, gender, duration and treatment of osteoporosis, number and duration of implants in function, and frequencies of toothbrushing, flossing and hygiene visits. Modified bleeding and plaque indices (mBI and mPI), peri-implant probing depth (PD) and crestal bone loss (CBL) were recorded. WS was collected and levels of AGEs and IL-17A were determined using enzyme linked immunosorbent assay. Sample-size estimation was done and statistical analyses were doing using the independent t- and Wilcoxon rank-sum tests. Statistical significance was marked for P-values that were below 0.01.

Results: In patients with (n = 24) and without (n = 27) osteoporosis, implants were in function for 6.3 ± 0.27 and 6.6 ± 0.5 years, respectively. There was no significant difference in peri-implant mBI, PD, mPI and CBL in both groups. Levels of AGE in patients with (119.6 ± 26.5 μg/ml) and without (91.5 ± 14.6 μg/ml) osteoporosis were comparable. Levels of whole salivary IL-17A in patients without and with osteoporosis were 4.6 ± 0.3 and 5.1 ± 0.8 pg/ml, respectively. Flossing of full mouth interproximal spaces once and twice daily toothbrushing daily was reported by 100% patients with osteoporosis. Among patients with osteoporosis 75% and 25% individuals were receiving professional dental prophylaxis every 4 and 6 months, respectively.

Conclusion: Within the limitations of the present study osteoporotic patients are not at an increased risk of peri-implant diseases and can demonstrate salivary AGE and IL-17A levels comparable to non-osteoporotic individuals as long as oral hygiene is stringently maintained.

Keywords: Advanced glycation endproducts, Alveolar bone loss, Osteoporosis, Probing depth

Introduction

Osteoporosis is an osseous disorder characterized by decreased bone density or low bone mass and structural deterioration of osseous tissues. This makes bones
vulnerable to pathological fracture [1]. Osteoporosis has been categorized into two main types: primary (most common form and often manifested in post-menopausal phase) and secondary (characterized as having a defined etiologic mechanism) [1]. From an immunoinflammatory perspective, glycoxidants or advanced glycation endproducts (AGE) are recognized as mediators of the development and pathogenesis of osteoporosis [2]. These endproducts are formed by non-enzymatic oxidation of proteins and lipid [3–5]; however, their production is significantly increased under a state of oxidative stress and/or inflammation. Accumulation of AGE within osseous tissues induces the formation of covalent cross-links with collagen and other proteins that jeopardizes osseous mechanical properties and disturbs bone remodelling [2]. The AGE also activate the formation of destructive inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-10, and IL-17A that facilitate and accelerate osteoclastic activity [6, 7]. Bisphosphonates are often used for the management of osteoporosis [8].

Dental implants (DI) can present survival rates ranging up to 100% [9, 10]; however, complications and failures in relation to DI therapy can happen in certain situations. A dilemma in clinical implant dentistry is the occurrence of peri-implantitis which if left untreated in a timely manner can result in extensive crestal bone loss (CBL) and even implant failure [11, 12]. Studies [13–15] have shown that osteoporosis compromises long-term survival of dental implants. According to Giro et al. [16] rate of implant failure is nearly 11% in patients with osteoporosis. In addition, the risk of development of ONJ is a serious consideration before and after DI placement and loading in patients undergoing BT, such as osteoporotic patients [17–19]. Moreover, bone-to-implant contact is compromised by approximately 50% in patients with osteoporosis. Nevertheless, a consensus as to whether or not osteoporosis is a risk-factor of peri-implant diseases is yet to be established [20]. An increased expression of AGE in whole saliva (WS), gingival crevicular fluid (GCF) and peri-implant sulcular fluid (PISF) has been linked with the etiopathogenesis of peri-implant diseases [21, 22]. Raised levels of AGE have been identified in the PISF of patients with peri-implantitis [21–23]. Similarly, IL-17A levels have also been identified in the PISF of patients with peri-implant diseases [24, 25]. There are however no studies that have assessed AGE and IL-17A levels in WS of patients with DI. A review of indexed literature also showed no studies that assessed whole salivary IL-17A and AGE levels among patients with and without osteoporosis.

The aim was to compare levels of AGEs and IL-17A in WS and peri-implant clinical and radiographic status of patients with and without osteoporosis at 6-years’ follow-up. The present study was based on the null hypothesis that there is no difference in whole salivary AGE and IL-17A levels and peri-implant clinical and radiographic status among patients with and without osteoporosis.

**Methods**

**Ethical guidelines**

The present investigation study was approved by the human subjects ethics board of the Sharavathi Dental College and Hospital, Shivamogga, Karnataka 577,204, India (21/2021-CR); and was carried out in accordance with the Helsinki Declaration of 1975, as revised in 2013. Participation was completely voluntary; and patients reserved the right to withdraw their participation at any stage of the study. There were no penalties associated with withdrawal. All patients were mandated to sign a consent form prior to inclusion in the present study.

**Inclusion and exclusion criteria**

The inclusion criteria were as follows: (a) patients that had DI-retained prosthesis for at least 5-years; (b) patients with medically diagnosed osteoporosis; (c) controls (individuals without a medical diagnosis of osteoporosis). Osteoporotic patients were defined as those with an overall bone mineral density (BMD) score of $< -2.5$ [26]. An overall BMD score of between -2.5 and -1.0 was evidence of osteopenia [26]. An overall BMD score over -1 was categorized as "normal" [26]. Self-reported tobacco product consumers, patients with other systemic diseases such as diabetes mellitus (DM), respiratory diseases and cardiovascular disorders (CD) and patients that had used antibiotics, and steroids within 90 days were excluded.

**Invitation letter, information sheet and consent form**

Patients with and without a history of osteoporosis that had undergone DI treatment for rehabilitation of missing teeth were recruited from the dental department of a local healthcare institution in Karnataka, India. Diagnosis of osteoporosis was verified from the patients’ medical records. Written invitation letters were posted to individuals with and without a diagnosis of osteoporosis along with an information sheet that described the purpose of the present study in simple words. A consent form was also posted and consenting individuals were requested to bring a signed version of the consent form to the Dental department of Sharavathi Dental College and Hospital, Shivamogga, Karnataka 577,204, India.

**Questionnaire**

Demographic information (sex, age in years, ethnic origin and gender) and information regarding daily
toothbrushing and interproximal flossing was recorded. Participants were also asked how often they went to a dentist or hygienist for dental prophylaxis.

Assessment of medical and dental records
Duration since diagnosis of osteoporosis and its treatment was retrieved from patients’ medical records. Information regarding DI characteristics (number of DI and their location in jaws, design, diameter and length, and mode of prosthesis retention) and duration for which, DI were functional was extracted from patient’s dental records.

Clinical and radiologic investigations
Modified bleeding and plaque indices (mBI [27] and mPI [27, 28]), and probing depth (PD) [29, 30] were measured using standard techniques. The CBL was measured on digital bitewing x-rays using a software program (Image Tool 3.0 Program, Department of Dental Diagnostic Science, University of Texas Health Science Center, San Antonio, TX, USA) as the linear distance from two-millimeters below the implant abutment interface to the crestal bone [31]. All clinical and radiographic investigations were done by a calibrated and blinded examiner (Kappa score 0.86).

Saliva collection and determination of levels of AGE and IL-17A
The WS samples were collected during early morning hours (between 7:30 am and 8:30 am) with the participants being in a fasting state. Saliva collection was done 24 h after clinical and radiographic assessments. The unstimulated WS was collected and salivary flow rate was determined using enzyme linked immunoabsorbent assay as described in other studies [32, 33]. Immediately upon WS collection and determination of flow rate, all samples were centrifuged at 1000 × g in a cold room at 4 °C for 15 min and the supernatant was collected. The supernatant was stored at −80 °C until further analysis. All WS supernatants were assessed for AGE and IL-17A levels within 24 h of collection. Levels of AGE were quantified using a commercial AGE kit (Oxiselect, Cell Biolabs, Inc., San Diego, CA, USA) in accordance with the protocol described in the study by Katz et al. [32] Briefly, each supernatant sample was diluted in phosphate buffered saline (PBS) in a 1:1 ratio. Spectrofluorometric analysis using a plate reader (BioTek Synergy HT, Winooski, VT, USA) was done to determine AGE levels. Intensity of fluorescence was read at emission and excitation wavelengths of 430 nm and 370 nm, correspondingly. Assessment of IL-17A levels was done using standard kits (MILLIPLEX-map-kit, Human cytokine/chemokine panel, Millipore, Billerica, MA, USA), which were used according to manufacturers’ instructions. Flow cytometry was performed as per the protocol described by Liukkonen et al. [34] All samples were assessed in triplicates for AGE and IL-17A levels. Levels of AGE and IL-17A were expressed in micrograms per milliliter (μg/ml) and picograms per milliliter (pg/ml), respectively. Levels of AGE and IL-17A were measured by a blinded and calibrated investigator (Kappa score 0.88).

Power and statistical analyses
Sample-size estimation (SSE) was done on data from a pilot investigation. Power analysis was done using the G*Power 3.1.9.7 program at a 95% confidence level and power factor of 85%. The primary parameters for SSE were PD and CBL in the study groups. According to the results of SSE, it was estimated that with an alpha of 1%, inclusion of at least 20 individuals per group would be needed to detect a 2 mm difference in PD and CBL in the study groups and attain a power of 85% after considering 15% dropouts. Statistical analyses were done using the independent t- and Wilcoxon rank-sum tests. Logistic regression analysis was done to determine correlation of salivary AGE and IL-17A with age, gender, peri-implant clinicoradiologic parameters, mode of prosthesis retention (cement versus screw retention) and duration of implants in function. Statistical significance was marked for P-values that were below 0.01. The statistician was blinded to the study groups.

Results
Response to invitation
Written invitation letters were posted to 77 patients (36 and 41 individuals with and without a diagnosis of osteoporosis, respectively). Twenty-six individuals did not respond to the invitation. Fifty-one individuals (24 and 27 with and without osteoporosis, respectively) signed the informed consent form and agreed to participate in the present study. Among patients with and without osteoporosis, 19 and 15 patients, respectively were females (Fig. 1).

Questionnaire
All participants (n=51) were Asian-Indian in origin. There was no significant difference in the mean ages of patients with (67.3 ± 5.1 years) and without (63.4 ± 2.8 years) osteoporosis. Among patients with osteoporosis, number of females were significantly higher than males (P<0.01). There was no significant difference in gender among individuals without osteoporosis. Toothbrushing twice daily was reported by 100% patients with and 81.5% patients without osteoporosis. Flossing of full mouth interproximal spaces once daily was reported by 100% and 77.8% patients with and
without osteoporosis, respectively. Seventy-five percent of patients with osteoporosis were receiving dental prophylaxis every four months. Six individuals (25%) with osteoporosis reported that they were visiting a hygienist biannually. In patients without osteoporosis, 66.7% and 33.3% individuals were receiving professional dental prophylaxis by a hygienist every 4 and 6 months, respectively (Table 1). All patients with osteoporosis had been prescribed vitamin supplementation, exercises and oral bisphosphonates by their healthcare providers.

**Implants**

In both groups, bone level and platform-switched implants were placed in the region of missing teeth in the anterior or posterior maxilla and/or mandible. The diameters and lengths of all implants ranged between 4–5 mm and 11–14 mm, respectively. All implants had been placed at a standardized insertion torque ranging between 30 and 35 Ncm; and 42.4% and 51.7% in patients with and without osteoporosis, respectively were restored with cement-retained restorations. In patients with and without osteoporosis, implants were in function for comparable durations (Table 2).

**Peri-implant parameters at six years’ follow-up**

None of the implants were lost up to six years’ follow-up (survival rate 100%). There was no significant difference in peri-implant mPI, mBI, PD and mesial and distal CBL around all implants among patients with osteoporosis and controls (Table 3). There was no significant correlation between PD and CBL and whole salivary AGE and IL-17A levels in the study population (Additional file 1: Fig. S1 and Additional file 2: Fig. S2, respectively). There was no correlation between salivary AGE and IL-17A levels and age, gender, duration of osteoporosis, duration of implants in function, jaw location, implant dimensions, mode of implant prosthesis retention, mPI and mBI (data not shown). None of the patients presented with clinical signs of ONJ such as pain and purulent discharge from exposed osseous tissues (Table 3).

**Salivary flow rate and AGE and IL-17A levels**

In patients with and without osteoporosis, there was no statistically significant difference in flow rate of WS and levels of AGE and IL-17A (Table 4).
The present observational study was based on the null hypothesis that there is no difference in whole salivary AGE and IL-17A levels and peri-implant clinical (PD, mBI and mPI) and radiographic (CBL) status among patients with and without osteoporosis. In summary, results of the present investigation showed that at approximately six years of follow-up scores of mBI, mPI, PD and CBL were statistically insignificant among patients with osteoporosis and controls (patients with - out osteoporosis). In other word, none of the patients presented with peri-implant diseases (peri-implant

| Parameters                                      | Patients with osteoporosis | Patients without osteoporosis (controls) | P value |
|-------------------------------------------------|----------------------------|----------------------------------------|---------|
| Implants (n)                                     | 33                         | 29                                     | 0.22    |
| Anterior maxilla                                 | 2 (6.1%)                   | 4 (13.8%)                              | 0.25    |
| Anterior mandible                               | 3 (9.1%)                   | 2 (6.9%)                               | 0.31    |
| Posterior maxilla*                              | 6 (18.2%)                  | 7 (24.1%)                              | 0.26    |
| Posterior mandible*                             | 22 (66.6%)                 | 16 (55.2%)                             | 0.19    |
| Implant abutment connection                      | Platform-switched          | Platform-switched                      | NA      |
| Insertion torque (Newton centimeters)           | 30 to 35 NCm               | 30 to 35 NCm                           | NA      |
| Implant diameter (in millimeters)               | 4 to 5 mm                  | 4.1 to 5 mm                            | NA      |
| Implant length (in millimeters)                 | 12 to 14 mm                | 11 to 14 mm                            | NA      |
| Implant prosthesis retention                     |                            |                                        |         |
| Cement retention (%)                            | 14 (42.4%)                 | 15 (51.7%)                             | 0.31    |
| Screw retention (%)                             | 19 (57.6%)                 | 14 (48.3%)                             | 0.29    |
| Duration for which, implants were in function (in years) | 6.3 ± 0.27 years          | 6.6 ± 0.5 years                        | 0.23    |
| Depth of implant placement                      | Bone level                 | Bone level                             | NA      |
| Implant supported dentures                       | None                       | None                                   | NA      |
| Implant supported dentures                       | None                       | None                                   | NA      |

| Parameters                                      | Patients with osteoporosis | Patients without osteoporosis (controls) | P value |
|-------------------------------------------------|----------------------------|----------------------------------------|---------|
| Peri-implant parameters                         |                            |                                        |         |
| Clinical                                        |                            |                                        |         |
| Modified bleeding index                         | 0.08 ± 0.0006              | 0.1 ± 0.0003                           | 0.16    |
| Modified plaque index                           | 0.2 ± 0.005                | 0.3 ± 0.002                            | 0.14    |
| Probing depth (in mm)                           | 1.06 ± 0.04 mm             | 1.2 ± 0.002 mm                         | 0.11    |
| Radiologic                                      |                            |                                        |         |
| Crestal bone loss (mesial) (in mm)              | 0.3 ± 0.005 mm             | 0.2 ± 0.005 mm                         | 0.18    |
| Crestal bone loss (distal) (in mm)              | 0.2 ± 0.003 mm             | 0.3 ± 0.007 mm                         | 0.16    |

| Parameters                                      | Patients with osteoporosis | Patients without osteoporosis (controls) | P value |
|-------------------------------------------------|----------------------------|----------------------------------------|---------|
| Peri-implant parameters                         |                            |                                        |         |
| Salivary flow rate (ml/min)                     | 0.13 ± 0.04 ml/min         | 0.12 ± 0.03 ml/min                     | 0.18    |
| Advanced glycation endproduct (µg/ml)           | 119.6 ± 26.5 µg/ml         | 91.5 ± 14.6 µg/ml                      | 0.09    |
| Interleukin-17 (pg/ml)                          | 5.1 ± 0.8 pg/ml            | 4.6 ± 0.3 pg/ml                        | 0.15    |

Discussion
The present observational study was based on the null hypothesis that there is no difference in whole salivary AGE and IL-17A levels and peri-implant clinical (PD, mBI and mPI) and radiographic (CBL) status among patients with and without osteoporosis. In summary,
mucositis or/and peri-implantitis) when they were clinically and radiologically evaluated at 6 years of follow-up. It is also important to mention that all DI were in function were lost at the follow-up. Moreover, results from laboratory-based investigations showed that whole salivary levels of AGE and IL-17A were comparable and within minimum detection range among individuals without and with osteoporosis. In this regard, the results of the present investigation support the null hypothesis; and demonstrated that a diagnosis of osteoporosis does not negatively influence the success and survival of DI. The authors support results presented in the study by Holahan et al. [35] in which, the influence of osteoporosis towards the survival of DI was retrospectively evaluated. In this study, more than 3,224 DI in 746 females aged at least 50 years were assessed [35]. The results showed that patients with osteoporosis were not at an increased risk of implant failure compared with controls [35].

In the current investigation the survival of dental implants in both groups (patients with and without osteoporosis) was 100%. There are a number of factors that seem to have influenced these outcomes. The study population evaluated in the current investigation seemed to be literate towards their oral health. Results obtained from the questionnaire revealed that all patients with osteoporosis were performing flossing of interproximal spaces and teeth brushing twice daily. Although percentages for these domestic oral hygiene maintenance protocols were slightly less in controls, they were statistically significant compared with osteoporotic patients. Moreover, all patients with osteoporosis and nearly 67% without osteoporosis were receiving professional dental prophylaxis by dental hygienists or dentists biannually. These factors may have helped maintain peri-implant health in both groups. Here, it is meaningful to mention that peri-implant health is characterized by features such as absence of (a) soft tissue swelling, (b) gingival redness and bleeding, and (c) CBL following initial healing [36]. All implants assessed in the present investigation fulfilled these criteria. From an immune-inflammatory perspective, the authors claim that routine oral hygiene maintenance not only reduces peri-implant swelling, redness, bleeding and bone loss but also minimizes the expression of salivary biomarkers of inflammation including AGE and IL-17A. The authors support results of a clinical study, in which Al-Amri et al. [37] concluded that as long as oral hygiene is routinely maintained, dental implants can remain clinically and radiologically stable in immuno-suppressed patients in a manner similar to their systemically healthy counterparts. Furthermore, none of the participants at ix years’ follow-up demonstrated any clinical signs of ONJ (such as exposure of bone and peri-implant tissue necrosis) in our study. In this context, a diagnosis of osteoporosis is not a contraindication to DI therapy and does not affect their long-term survival as long as oral hygiene is stringently maintained. Similar conclusions were made by Chen et al. [38] and de Medeiros et al. [39].

It has been reported that DI that are placed in tobacco-smokers are more likely to demonstrate signs and symptoms of peri-implant mucositis and peri-implantitis compared with individuals not using any type of tobacco products [21, 40]. Moreover, AGE levels are elevated in PISF of tobacco-smokers than non-smokers [21]. Similarly, from a systemic perspective, metabolic diseases such as poorly-controlled DM pose an increased risk for peri-implant diseases in susceptible patients [12, 41]. According to Romana and Li-Yu [42] the prevalence of type-2 DM in patients with osteoporosis is approximately 22%. Therefore, it is strongly suggested that patients with osteoporosis should be screened for DM. In the present study, patients with self-reported systemic diseases other than osteoporosis (such as DM) were excluded; however, their glycemic levels were not screened using traditional tests such as assessment of fasting plasma glucose or hemoglobin A1c levels. Nevertheless, upon evaluation of the patients’ medical records, none of the patients that agreed to participate in the present study had a diagnosis of systemic diseases such as DM, respiratory conditions and/or CD. It is likely that osteoporotic patients with impaired glycemic levels (hyperglycemia) are an increased risk of developing peri-implant diseases compared with non-diabetic individuals with osteoporosis. This warrants additional studies as previously recommended in a meta-analysis by Chen et al. [38] Another limitation of the present investigation is that self-reported tobacco-product consumers (such as cigarette smokers) were not sought. Tobacco-smoking is an independent risk factor of low BMD and bone loss around teeth and DI [31, 43–45]. It is hypothesized that salivary levels of AGE and IL-17A are high and periodontal and peri-implant clinicoradiographic signs are worse in diabetic patients with osteoporosis and smokers with impaired BMD. Further studies are required to test this hypothesis.

**Conclusion**

Within the limitations of the present study osteoporotic patients are not at an increased risk of peri-implant diseases and can demonstrate salivary AGE and IL-17A levels comparable to non-osteoporotic individuals as long as oral hygiene is stringently maintained.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12903-022-02591-7.

Additional file 1: Fig. S1. Correlation between levels of advanced glycation endproducts and peri-implant probing depth and clinical attachment loss in the study population.

Additional file 2: Fig. S2. Correlation between levels of interleukin-17A and peri-implant probing depth and clinical attachment loss in the study population. Correlation between PD and CBL and whole salivary AGE and IL-17A levels in the study population.

Acknowledgements

Not applicable.

Author contributions

Conceptualization, FA; methodology, FA, NA, FA; software, NA, FA and NA; validation, FA, NA, FA, FKA; formal analysis, FA; investigation, FA, NA, FA, resources, FA; data curation, NA; writing—original draft preparation, FA, NA, FA and FKA; writing—review and editing, FA, NA, FA and FKA; visualization, FA, NA, FA and FKA; supervision, FA; project administration, FA. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The research data and/or materials are not publicly available as the authors did not entail consents to publish this data; however, the data is available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Written informed consent was obtained from all subjects. The present investigation study was approved by the human subjects ethics board of the Sharavathi Dental College and Hospital, Shimavogga, Karnataka 577204, India (21/2021-CR), and was carried out in accordance with the Helsinki Declaration of 1975, as revised in 2013. Participation was completely voluntary, and patients reserved the right to withdraw their participation at any stage of the study. There were no penalties associated with withdrawal.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest and there was no external source of funding for the present study.

Author details

1Department of Prosthodontics, School of Dentistry, Prince-Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. 2Department of Oral and Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. 3Department of Dental Medicine, Sharavathi Dental College and Hospital, Shimavogga, Karnataka 577204, India. 4Department of Prosthodontics, College of Dentistry, Imam Abdulrahman Bin Faisal University, PO. Box 1982, Dammam 31441, Saudi Arabia.

Received: 13 July 2022 Accepted: 14 November 2022 Published online: 24 November 2022

References

1. Dobbs MB, Buckwalter J, Saltzman C. Osteoporosis: the increasing role of the orthopaedist. Iowa Orthop J. 1999;19:43–52.
2. Sanguinetti R, Puddu A, Mach F, Montecucco F, Viviani GL. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediat Inflamm. 2014;2014:975872.
3. Gurav AN. Advanced glycation end products: A link between periodontitis and diabetes mellitus? Curr Diabetes Rev. 2013;9(5):355–61.
4. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann Periodontol. 2001;6(1):113–8.
5. Lalla E, Lamster IB, Schmidt AM. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. Ann Periodontol. 1998;3(1):13–9.
6. Pietropaoli D, Ortu E, Severino M, Ciarrocchi I, Gatto R, Monaco A. Glycation and oxidative stress in the failure of dental implants: a case series. BMC Res Notes. 2013;6:296.
7. DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem. 2012;113(9):2895–902.
8. Naylor KE, Jacques RM, Paggiossi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Castell R. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27(11):21–31.
9. Donkewicz P, Benz K, Kloss-Brandstätter, A. Jackowski J. Survival rates of dental implants in autogenous and allogeneic bone blocks: a systematic review. Medicina. 2021;57(12):1388.
10. Carosi P, Lorenzi C, Lio F, Laurenti M, Ferrigno N, Arcuri C. Short implants (<6mm) as an alternative treatment option to maxillary sinus lift. Int J Oral Maxillofac Surg. 2021;50(11):1502–10.
11. Ali D, Baskaradoss JK, Joseph BK. Cortisol levels in the peri-implant sulcular fluid of type-2 diabetic and non-diabetic patients with peri-implantitis. Oral Health Prev Dent. 2022;20(1):219–26.
12. Alqahtani F, Alqahtani N, Alkhaldi F, Devang Divakar D, Al-Khayera AA, Javed F. Clinicoradiographic markers of peri-implantitis in cigarette-smokers and never-smokers with type 2 diabetes mellitus at 7-years follow-up. J Periodontol. 2020;91(9):1132–8.
13. Becker W, Hjooel PP, Becker BE, Willeham H. Osteoporosis and implant failure: an exploratory case-control study. J Periodontol. 2000;71(4):625–31.
14. Grasa A, Vezz-Keenan A. Is osteoporosis a risk factor for implant survival or failure? Evid Based Dent. 2018;19(2):51–2.
15. Bryant SR. The effects of age, jaw site, and bone condition on oral implant outcomes. Int J Prosthodont. 1998;11(5):470–70.
16. Giro G, Chambrone L, Goldstein A, Rodrigues JA, Zenbibo E, Feres M, Figueiredo LC, Cassoni A, Shibli JA. Impact of osteoporosis in dental implants: a systematic review. World J Orthop. 2015;6(2):311–5.
17. Javed F, Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol. 2010;81(4):479–84.
18. Romero-Ruiz JM, Romero-Serrano M, Serrano-González A, Serrera-Frigallo M, Gutiérrez-Pérez JL, Torres-Lagares D. Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2021;26(3):e314–26.
19. Ryu JJ, Kim HY, Kwon YD. Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study. Clin Oral Implants Res. 2021;32(4):437–47.
20. Alqahtani AF, Radi IA. No clear evidence regarding the effect of osteoporosis on dental implant failure. J Evid Based Dent Pract. 2016;16(2):124–6.
21. Al-Aali KA, Al-Helal A, Alhamoudi N, Alhenaki AM, Javed F, Abdullaajbar T. Assessment of advanced glycation end products in the peri-implant sulcular fluid among moderate cigarette-smokers and nonsmokers with peri-implantitis. Clin Implant Dent Relat Res. 2020;22(3):380–6.
22. Al-Souvygh ZH, Ghiavi S, Sargs K, Vohra F, Akram Z. Peri-implant conditions and levels of advanced glycation end products among patients with different glyemic control. Clin Implant Dent Relat Res. 2018;20(3):345–51.
23. Alrabiah M, Al‑Aali KA, Al‑Soyygh ZH, Binnahfouz AM, Mokeem SA, Abdulkarim T. Association of advanced glycation end products with peri‑implant inflammation in prediabetes and type 2 diabetes mellitus patients. Clin Implant Dent Relat Res. 2018;20(4):535–40.

24. Gleiznys D, Krauciuunas A, Maminskas J, Stumbras A, Giedrimiene O, Niekrais C, Gleiznys A, Sakalauskiene J, Vitkauskiene A. Expression of interleukin‑17, tumor necrosis factor‑alpha, and matrix metalloproteinase‑8 in patients with chronic peri‑implant mucositis. Med Sci Monit. 2021;27:e932243.

25. Severino VC, Napimoga MH, de Lima Pereira SA. Expression of IL‑6, IL‑10, IL‑17 and IL‑23 vary in relation to periodontal status, J Periodontol. 2019;80(12):1484–91.

26. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. The scientific advisory board and the board of national societies. Osteoporos Int. 1996(6):356–61.

27. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J. 1975(25):229–35.

28. Armaitge GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol. 2000;2000(34):9—21.

29. Armitage GC, Mannberg GR, Loe H. Microscopic evaluation of clinical measurements of connective tissue attachment levels. J Clin Periodontol. 1977;4(3):173–90.

30. Avetisyan A, Markaryan M, Rokaya D, Tovani‑Palone MR, Zafar MS, Khurshid Z, Vardanyan A, Heboyan A. Characteristics of periodontal tissues in prosthetic treatment with fixed dental prostheses. Molecules. 2021;26(5):1331.

31. Javed F, Näsström K, Benchimol D, Altamash M, Klinge B, Engström PE. Comparison of periodontal and socioeconomic status between subjects with type 2 diabetes mellitus and non‑diabetic controls. J Periodontol. 2007;78(11):2112–9.

32. Katz J, Moreb J, Baitinger C, Singer C, Caudle RM. Advanced glycation endproducts (AGEs) in saliva of patients with multiple myeloma - a pilot study. Leuk Lymphoma. 2017;58(12):2934–8.

33. Javed F, Al‑Zawawi AS, Allemam KS, Almatroudi A, Mehmoood A, Divakar DQ, Al‑Kheraif AA. Peri‑implant health, peri‑implantitis. Arch Oral Biol. 2011;56(8):823–8.

34. Liukkonen J, Gürsoy UK, Pussinen PJ, Suominen AL, Könönen E. Salivary interleukin‑1ß, IL‑17A, and IL ‑8 in the peri‑implant crevicular fluid of patients with peri‑implantitis. Arch Oral Biol. 2011;56(8):823–8.

35. Holahan CM, Koka S, Kennel KA, Weaver AL, Assad DA, Regennitter FJ, Kademani D. Effect of osteoporotic status on the survival of titanium dental implants. Int J Oral Maxillofac. Implants. 2008;23(5):905–10.

36. Renvert S, Persson GR, Pirn FQ, Camargo PM. Peri‑implant health, peri‑implant mucositis, and peri‑implantitis: case definitions and diagnostic considerations. J Periodontol. 2019;80(Suppl 1):S304–12.

37. Al‑Amri MD, Kellesarian SV, Al‑Kheraif AA, Malmstrom H, Javed F, Romanos GE. Effect of oral hygiene maintenance on HbA1c levels and peri‑implant parameters among immediately‑loaded dental implants placed in type‑2 diabetic patients: 2 years follow‑up. Clin Oral Implants Res. 2016;27(11):1439–43.

38. Chen H, Liu N, Xu X, Qu X, Lu E. Smoking, radiotherapy, diabetes and osteoporosis as risk factors for dental implant failure: a meta‑analysis. PLoS ONE. 2013;8(8):e71955.

39. de Medeiros F, Kudo GAH, Leme BG, Saraiva PP, Verri FR, Honório HM, Pellizzer EP. Santiago Junior JF. Dental implants in patients with osteoporosis: a systematic review with meta‑analysis. Int J Oral Maxillofac. Surgery. 2018;47(4):480–91.

40. Alqahtani F, Alqahtani M, Shafqat SS, Akram Z, Al‑Kheraif AA, Javed F. Efficacy of mechanical debridement with adjunctive probiotic therapy in the treatment of peri‑implant mucositis in cigarette‑smokers and never‑smokers. Clin Implant Dent Relat Res. 2019;21(4):734–40.

41. Patel V, Sadiq MS, Najeeb S, Khurshid Z, Zafar MS, Heboyan A. Effects of metformin on the bioactivity and osseointegration of dental implants: a systematic review. J Taibah Univ Med Sci. 2022.

42. Sta Romana M, Li‑Yu JT. Investigation of the relationship between type 2 diabetes and osteoporosis using Bayesian inference. J Clin Densitom. 2007;10(4):386–90.

43. Trevisan C, Alessi A, Girotti G, Zanforlini BM, Bertocco A, Mazzochin M, Zoccarato F, Provesan F, Danain M, Giannini S, et al. The impact of smoking on bone metabolism, bone mineral density and vertebral Fractures in postmenopausal women. J Clin Densitom. 2020;23(3):381–9.

44. Javed F, Rahman I, Romanos GE. Tobacco‑product usage as a risk factor for dental implants. Periodontol. 2019;81(1):48–56.

45. Sriraneepong V, Heboyan A, Zafar MS, Khurshid Z, Maraya A, Fernandes GV, Rokaya D. Fixed prosthetic restorations and periodontal health: a narrative review. J Funct Biomater. 2022;13(1):15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.